Replies to post #5454 on GTC Biotherapeutics (fka GTCB)

[dewophile]

sounds to me they have to actively modify the production platform, either tweaking the vector or something more downstream in production, to generate a longer half life (unlike the naturally lower fucosylation that occurs with transgenics that conveniently enhances ADCC for cytotoxic Abs)
just a guess